A compound called tubastatin inhibits an enzyme-linked cell signaling pathway associated with lung tissue scarring, reducing pulmonary fibrosis, a study reports. The research on the HDAC6 enzyme in laboratory cell cultures and mice was able to identify only part of the mechanism involved in alleviating the scarring, however. The full…
Enzyme-inhibiting Compound Tubastatin Alleviates Pulmonary Fibrosis in Mice, Study Shows
For a patient with a life-threatening illness, there is nothing more difficult than asking others to help you with a task that you were once able to do independently. Having to do this highlights the fact that as a chronic illness progresses, including pulmonary fibrosis (PF), a patient’s physical abilities often regress.
Inhibiting an enzyme called phosphoglycerate dehydrogenase prevented additional lung tissue scarring in a mouse model of pulmonary fibrosis, a study reports. The discovery means scientists might be able to develop a PF therapy by targeting the enzyme, which is involved in metabolism, or transforming food into energy. The enzyme is…
I had an experience last week that reminded me of how I am still adjusting to my changing energy levels. A friend stopped by to visit and we had a nice time catching up. She was here for an hour and a half, and I was sitting…
The U.S. Food and Drug Administration has granted Fast Track designation to PBI-4050, ProMetic Life Sciences’ potential treatment for idiopathic pulmonary fibrosis, or IPF. Regulators recently approved ProMetic’s Investigational New Drug application for PBI-4050 and the company’s design for pivotal Phase 2/3 clinical trials of the therapy. A pivotal…
If you’re a member of the PF community, you’re well aware of how little the general public knows about the disease. It’s important that we all work together to raise awareness. Awareness results in more fundraising efforts, which means more dollars, which means more research, and eventually, hopefully, that means…
With the exception of being on antibiotics again for a bacterial infection that tried to start in my ears, nose, and throat, I am feeling pretty well these days. I am tired, but that is to be expected, and most of my harder days now are from the…
After reading other columns on this site, I’ve come to realize I’m not the only person with a lung disease dealing with sleep issues. After being diagnosed with idiopathic pulmonary fibrosis (IPF) in early 2016, I don’t recall sleep ever having been a problem until recently, in the last…
Ofev (nintedanib) is effective at slowing idiopathic pulmonary fibrosis (IPF) progression in patients over time regardless of their degree of lung function at the beginning of treatment, according to new results from an extension of a Phase 3 clinical trial. Ofev, by Boehringer Ingelheim, was approved by the U.S. Food and Drug…
Researchers have identified a variation of the AKAP13 gene that they say increases people’s susceptibility to developing idiopathic pulmonary fibrosis. An article about their discovery, published in The Lancet Respiratory Medicine, is titled “Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study.” Previous…
